Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | LTK | P29376 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897590 | 0.90 | LMNA (0.44) | FGFR1DAPK3PRKD3MAP4K4ABL1 | |
| SCHEMBL2897018 | 0.82 | LMNA (0.49) | FGFR1DAPK3PRKD3MAP4K4ABL1 | |
| SCHEMBL2369059 | 0.81 | FGFR1 (0.56) | FGFR1DAPK3PRKD3MAP4K4ABL1 | |
| SCHEMBL380700 | 0.77 | KDR (0.44) | FGFR1DAPK3PRKD3MAP4K4ABL1 | |
| SCHEMBL2898733 | 0.77 | LMNA (0.51) | FGFR1DAPK3PRKD3MAP4K4ABL1 | |
| SCHEMBL3387889 | 0.76 | LMNA (0.50) | FGFR1DAPK3PRKD3MAP4K4ABL1 | |
| SCHEMBL2368941 | 0.74 | LMNA (0.43) | FGFR1DAPK3PRKD3MAP4K4ABL1 | |
| SCHEMBL3381246 | 0.74 | LMNA (0.43) | FGFR1DAPK3PRKD3MAP4K4ABL1 | |
| SCHEMBL2903658 | 0.74 | LMNA (0.43) | FGFR1MAPK1LMNASMN1; SMN2HPGD | |
| SCHEMBL3383431 | 0.73 | ALDH1A1 (0.44) | FGFR1DAPK3PRKD3MAP4K4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879899-B1 | THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2010-08-04 | — | — | EP | claimed |
| US-7576212-B2 | Thieno[2,3-B] pyridines as potassium channel inhibitors | XENTION LIMITED (GB) | 2009-08-18 | — | — | US | claimed |
| EP-1879899-A1 | THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Xention Discovery Limited (GB) | 2008-01-23 | — | — | EP | claimed |
| US-20060183768-A1 | Compounds | XENTION DISCOVERY LTD. (GB) | 2006-08-17 | — | — | US | claimed |
| WO-2006061642-A1 | COMPOUNDS | XENTION DISCOVERY LIMITED (GB) | 2006-06-15 | — | — | WO | claimed |
| US-8193215-B2 | Thieno[2 3-b]pyridines as potassium channel inhibitors | XENTION LIMITED (GB) | 2012-06-05 | — | — | US | disclosed |
| EP-1879899-B1 | THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2010-08-04 | — | — | EP | disclosed |
| US-20100041695-A1 | Thieno[2,3-b]pyridines as Potassium Channel Inhibitors | XENTION LIMITED (GB) | 2010-02-18 | — | — | US | disclosed |
| US-7576212-B2 | Thieno[2,3-B] pyridines as potassium channel inhibitors | XENTION LIMITED (GB) | 2009-08-18 | — | — | US | disclosed |
| EP-1879899-A1 | THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Xention Discovery Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-20060183768-A1 | Compounds | XENTION DISCOVERY LTD. (GB) | 2006-08-17 | — | — | US | disclosed |
| WO-2006061642-A1 | COMPOUNDS | XENTION DISCOVERY LIMITED (GB) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041695-A1 | Thieno[2,3-b]pyridines as Potassium Channel Inhibitors | SCN8A, SCN1B, SCN2B | FGFR1 1604/4885DAPK3 2892/4885PRKD3 3412/4885 |
| US-20060183768-A1 | Compounds | SCN7A, CBR3, SCN8A | FGFR1 1330/4885DAPK3 3072/4885PRKD3 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.